Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Solid Tumors 2Lung Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Histologically or Cytologically Documented Solid Tumors 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

motesanib diphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid cancer, Hurthle cell × motesanib diphosphate × Clear all
NCT00121628 2013-10-09

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Amgen

Phase 2 Completed
184 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡